Other Balance Sheet Information (Tables)

9 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Accounts Receivable

The following is a summary of accounts receivable at June 30, 2021 and September 30, 2020 (in thousands):

	June 30,		September 30,
	2021		2020
Accounts receivable	$	238,890	$	195,587
Less allowance for expected credit losses		(4,737)		(7,216)
Less allowance for sales returns		(74)		(80)
Accounts receivable, net	$	234,079	$	188,291

Summary of Inventories

The decrease in the allowance for expected credit losses from September 30, 2020 is due to collections of previously reserved trade receivables in the Brooks Life Sciences Services segment during the first quarter of fiscal year 2021.

The following is a summary of inventories at June 30, 2021 and September 30, 2020 (in thousands):

	June 30,		September 30,
	2021		2020
Inventories
Raw materials and purchased parts	$	98,997	$	73,609
Work-in-process		21,356		16,461
Finished goods		34,367		24,764
Total inventories	$	154,720	$	114,834

Product Warranty and Retrofit Activity on Gross Basis

The following is a summary of product warranty and retrofit activity on a gross basis for the three and nine months ended June 30, 2021 and 2020 (in thousands):

Activity -Three Months Ended June 30, 2021
Balance						Balance
March 31,						June 30,
2021		Accruals		Costs Incurred		2021
$	8,044	$	1,892	$	(1,804)	$	8,132
Activity -Three Months Ended June 30, 2020
Balance						Balance
March 31,						June 30,
2020		Accruals		Costs Incurred		2020
$	7,910	$	1,380	$	(1,409)	$	7,881
Activity -Nine Months Ended June 30, 2021
Balance						Balance
September 30,						June 30,
2020		Accruals		Costs Incurred		2021
$	8,201	$	5,990	$	(6,059)	$	8,132
Activity -Nine Months Ended June 30, 2020
Balance						Balance
September 30,						June 30,
2019		Accruals		Costs Incurred		2020
$	7,175	$	6,033	$	(5,327)	$	7,881